Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 | Eli Lilly and Company

The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.

Read the full article here

Related Articles